Pricing Log in Create free account
Friday 6 November 2026 Export BIO.B’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO.B Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.8%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

379.50 15.35 +4.22%
Market cap
$10.3B
P/E
9.9×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
3.24
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Rad Laboratories, Inc. (BIO.B) valuation and DCF model

What the price implies · reverse DCF

Bio-Rad Laboratories, Inc. is not valued here: no recent price.

Last 5 years, reported
−10.1%
Last 10 years, reported
18.5%

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Medical Devices).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 9.95× 7.38× 38.53× 74% below 25.58× 61% below
P/FCF 30.69× 54.19× 49.15× 38% below 28.81× 7% above
P/B 1.34× 1.24× 1.55× 14% below 2.48× 46% below
EV/EBITDA — 59.27× 48.85× — 11.51× —
EV/Sales 3.74× 3.55× 4.16× 10% below 2.72× 38% above
P/E P/FCF P/B EV/EBITDA EV/Sales
31.06×65.33×99.59×133.86×10Y avg 49.15×2016201820192020202120222023202420252026

BIO.B trades at 30.69× P/FCF, against a 10-year average of 49.15× (range 22.49×–143.80×). That is cheaper than 78% of the last 9 year-end readings.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.